Evidence map›Paper›PMID 41491032›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

The integrated diagnostic strategy of performing PSMA PET/CT followed by MRI improves the diagnostic accuracy of prostate cancer.

Jiangyu Ma, Chu Wang, Miao Wang, Chao Ren, Zhenghai Huang, Yonghui Chen, Shuaitao Xiong, Jingxin Yang, Ming Liu, Li Huo

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jiangyu Ma *Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Chu Wang *Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Miao WangDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Chao RenDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Zhenghai HuangTheranostics and Translational Research Center, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China.
Yonghui ChenDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.
Shuaitao XiongDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Jingxin YangDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Ming LiuDepartment of Urology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
Li HuoDepartment of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Center for Rare Diseases Research, Beijing Key Laboratory of Molecular Targeted Radiopharmaceutical Development and Translational Application in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. huoli@pumch.cn.ORCID 0000-0003-1216-083X

Funding

CAMS Innovation Fund for Medical Sciences (CIFMS) 2025-I2M-C&T-B-093National High Level Hospital Clinical Research Funding 2022-PUMCH-B-072Peking Union Medical College Hospital Talent Cultivation Program Category D UHB12835
6 · The paper itself

Abstract

purposePRIMARY score uses intraprostatic uptake patterns and uptake intensity of PSMA and has good performance in identifying clinically significant prostate cancer (csPCa). However, diagnostic accuracy is not satisfying in patients with PRIMARY score of 3 and 4, which may account for the relatively low specificity of PRIMARY score. MRI may improve the accuracy of PRIMARY score. This study aims to investigate the added value of bpMRI to Al

methodsThis is a retrospective analysis of a prospectively collected dataset. Al

results181 patients were included in this analysis. The incidence of csPCa in PRIMARY score 1-5 is 0 (0/18), 7.7% (3/39), 15.4% (2/13), 55.0% (22/40) and 87.3% (62/71). The sensitivity, specificity, PPV and NPV of PRIMARY score are 96.6%, 58.7%, 69.4% and 94.7%. After diagnostic refinement via bpMRI in patients with PRIMARY score 3 or 4, 22 patients were changed to the negative group. Only 3 of 22 patients, all with ISUP 2, had csPCa. The sensitivity, specificity, PPV, and NPV of the new diagnostic pathway were 93.3%, 79.3%, 81.4% and 92.4%. The specificity increased significantly (p < 0.001) while the sensitivity remained the same (p = 0.25).

conclusionAddition of bpMRI in patients with PRIMARY scores of 3 or 4 improved specificity for diagnosing csPCa while maintaining comparable sensitivity levels. Only a small proportion of patients were additionally missed, all of whom had low pathological grades. The novel diagnostic strategy represents an effective, safe, and efficient approach to identify csPCa with significant clinical application value.

Indexed as

Magnetic Resonance ImagingPositron Emission Tomography Computed TomographyProstatic NeoplasmsAgedAged, 80 and overGlutamate Carboxypeptidase IIHumansMaleMiddle AgedRetrospective StudiesSensitivity and SpecificityGlutamate Carboxypeptidase IIMRIProstate cancerPSMA PET/CTSpecificity, PRIMARY score

Identifiers

PMID41491032

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.